Evidence map›Paper›PMID 40079390›Full record

ArticleACS chemical biology2025

Single-Chain Nanobody Inhibition of Notch and Avidity Enhancement Utilizing the β-Pore-Forming Toxin Aerolysin.

Andrew C D Lemmex, Jeremy Allred, Jason Ostergard, Jake Trask, Hannah N Bui, Michael J M Anderson, Benjamin Kopp, Oakley Streeter, Adam T Smiley, Natalia S Babilonia-Díaz and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Andrew C D LemmexUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Jeremy AllredUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Jason OstergardUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Jake TraskUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Hannah N BuiUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Michael J M AndersonUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.ORCID 0000-0001-5116-1427
Benjamin KoppUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Oakley StreeterUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Adam T SmileyUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.ORCID 0000-0002-3891-8242
Natalia S Babilonia-DíazUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Bruce R BlazarUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
LeeAnn HigginsUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Peter M GordonUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.ORCID 0000-0002-3159-1881
Joseph M MurettaUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.
Wendy R GordonUniversity of Minnesota, Twin Cities, Minneapolis, Minnesota 55409, United States.ORCID 0000-0001-7696-5560

Funding

TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3M
TRAINING FOR FUTURE BIOTECHNOLOGY DEVELOPMENTT32GM008347 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SCHMIDT-DANNERT, CLAUDIA · 1990 to 2021
$11.0M
Mechanism and modulation of Amyloid Precursor Protein proteolysisR35GM119483 · NIGMS · UNIVERSITY OF MINNESOTA · PI WENDY RYAN GORDON · 2016 to 2026
$4.6M
Training the Next Generation of Chemical BiologistsT32GM132029 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson, William Charles Krause Pomerantz · 2019 to 2026
$2.7M
A transformative next-generation Orbitrap Tribrid system for the UMN and Upper MidwestS10OD028717 · OD · UNIVERSITY OF MINNESOTA · PI GRIFFIN, TIMOTHY J. · 2020 to 2020
$1.2M
Engineering Protein Modulators of Notch Activation for T-cell immunotherapyR33CA272331 · NCI · UNIVERSITY OF MINNESOTA · PI GORDON, WENDY RYAN, MURETTA, JOSEPH M. · 2023 to 2025
$1.1M
NCI NIH HHS R33 CA272331NIAMS NIH HHS T32 AR007612NIGMS NIH HHS R35 GM119483NIGMS NIH HHS T32 GM008347NIGMS NIH HHS T32 GM132029NIH HHS S10 OD028717
6 · The paper itself

Abstract

Notch plays critical roles in developmental processes and disease pathogenesis, which have led to numerous efforts to modulate its function with small molecules and antibodies. Here we present a nanobody inhibitor of Notch signaling derived from a synthetic phage-display library targeting the Notch negative regulatory region (NRR). The nanobody inhibits Notch signaling in a luciferase reporter assay with an IC

Indexed as

Bacterial ToxinsPore Forming Cytotoxic ProteinsReceptors, NotchSingle-Domain AntibodiesCell Line, TumorCell ProliferationHumansSignal TransductionSingle-Chain AntibodiesaerolysinBacterial ToxinsPore Forming Cytotoxic ProteinsReceptors, NotchSingle-Chain AntibodiesSingle-Domain Antibodies

Identifiers

PMID40079390
PMCPMC12184807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.